NCT05798923View on ClinicalTrials.gov

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

May 16, 2025

Study Completion Date

September 30, 2027

Conditions
Pulmonary Hypertension
Interventions
DRUG

LAM-001

LAM-001 administered via dry powder inhalation

Trial Locations (4)

44195

Cleveland Clinic, Cleveland

85748

University of Arizona, Tucson

06510

Yale New Haven Hospital, New Haven

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

OrphAI Therapeutics

INDUSTRY

NCT05798923 - A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension | Biotech Hunter | Biotech Hunter